Patent(s) and the Corresponding Patented Drug(s) |
Top |
World Intellectual Property Organization (WIPO) |
Patent ID |
WO2007019083 |
Title |
Pyrimidine Compounds As Serotonin Receptor Modulators. |
Abstract |
Certain pyrimidine-containing compounds are serotonin receptor modulators useful in the treatment of serotonin-mediated diseases. |
Applicant(s) |
Janssen Pharmaceutica Nv |
Representative Drug(s) |
D00YGY |
Drug Info
|
Ki = 20 nM |
Click to Show More |
[1] |
2
|
D0P9VX
|
Drug Info
|
Ki = 70 nM
|
[1] |
3
|
D0B7NS
|
Drug Info
|
Ki = 90 nM
|
[1] |
4
|
D0N2VA
|
Drug Info
|
Ki = 900 nM
|
[1] |
5
|
D0U9UH
|
Drug Info
|
Ki = 1020 nM
|
[1] |
6
|
D0SE9K
|
Drug Info
|
Ki = 1170 nM
|
[1] |
7
|
D08DJY
|
Drug Info
|
Ki = 1000 nM
|
[1] |
Patent ID |
WO2003086306 |
Title |
5Ht2C Receptor Modulators. |
Abstract |
The present invention relates to novel compounds of: (Formula I); which act as 5HT2C receptor modulators. These compounds are useful in pharmaceutical compositions whose use includes the treatment of obesity. |
Applicant(s) |
Arena Pharmaceuticals, Inc |
Representative Drug(s) |
D0L4UC |
Drug Info
|
IC50(IP accumulation assay) = 1.4 nM |
Click to Show More |
[1] |
2
|
D03IZY
|
Drug Info
|
IC50(IP accumulation assay) = 2.1 nM
|
[1] |
3
|
D0A5FR
|
Drug Info
|
IC50(IP accumulation assay) = 4.2 nM
|
[1] |
4
|
D0T5ER
|
Drug Info
|
IC50(IP accumulation assay) = 4.5 nM
|
[1] |
5
|
D0BU6K
|
Drug Info
|
EC50 = 5 nM
|
[1] |
6
|
D0I3QY
|
Drug Info
|
IC50(IP accumulation assay) = 6.3 nM
|
[1] |
7
|
D0GW5F
|
Drug Info
|
IC50(IP accumulation assay) = 12.1 nM
|
[1] |
8
|
D0HV0D
|
Drug Info
|
N.A.
|
[1] |
9
|
D0OA6W
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2007081299 |
Title |
Tricyclic Indeno-Pyrrole Derivatives As Serotonin Receptor Modulators. |
Abstract |
The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity). |
Applicant(s) |
Athersys, Inc |
Representative Drug(s) |
D0AA9F |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D0AV8R
|
Drug Info
|
N.A.
|
[1] |
3
|
D0SO0F
|
Drug Info
|
N.A.
|
[1] |
4
|
D0WS6Y
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2006028961 |
Title |
Tricyclic Heteroaryl Piperazines, Pyrrolidines and Azetidines As Serotonin Receptor Modulators. |
Abstract |
The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity). |
Applicant(s) |
Athersys, Inc |
Representative Drug(s) |
D0AA9F |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D0AV8R
|
Drug Info
|
N.A.
|
[1] |
3
|
D0SO0F
|
Drug Info
|
N.A.
|
[1] |
4
|
D0WS6Y
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2006004931 |
Title |
Substituted Azepine Derivatives As Serotonin Receptor Modulators. |
Abstract |
The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity). |
Applicant(s) |
Athersys, Inc |
Representative Drug(s) |
D00DFK |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D00YRD
|
Drug Info
|
N.A.
|
[1] |
3
|
D06VJM
|
Drug Info
|
N.A.
|
[1] |
4
|
D07KZR
|
Drug Info
|
N.A.
|
[1] |
5
|
D09EPG
|
Drug Info
|
N.A.
|
[1] |
6
|
D0AI8S
|
Drug Info
|
N.A.
|
[1] |
7
|
D0AJ0O
|
Drug Info
|
N.A.
|
[1] |
8
|
D0BD3M
|
Drug Info
|
N.A.
|
[1] |
9
|
D0FK0Y
|
Drug Info
|
N.A.
|
[1] |
10
|
D0FS3J
|
Drug Info
|
N.A.
|
[1] |
11
|
D0KO2E
|
Drug Info
|
N.A.
|
[1] |
12
|
D0MQ7F
|
Drug Info
|
N.A.
|
[1] |
13
|
D0R6EF
|
Drug Info
|
N.A.
|
[1] |
14
|
D0UL9W
|
Drug Info
|
N.A.
|
[1] |
15
|
D0YO2O
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2002040456 |
Title |
Piperazinylpyrazine Compounds As Agonist or Antagonist of Serotonin 5Ht-2 Receptor. |
Abstract |
A compound of the general formula (I), wherein R1, R2, X, Y and Z are as described in the specification. |
Applicant(s) |
Biovitrum Ab |
Representative Drug(s) |
D00DFK |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D00YRD
|
Drug Info
|
N.A.
|
[1] |
3
|
D06VJM
|
Drug Info
|
N.A.
|
[1] |
4
|
D07KZR
|
Drug Info
|
N.A.
|
[1] |
5
|
D09EPG
|
Drug Info
|
N.A.
|
[1] |
6
|
D0AI8S
|
Drug Info
|
N.A.
|
[1] |
7
|
D0AJ0O
|
Drug Info
|
N.A.
|
[1] |
8
|
D0BD3M
|
Drug Info
|
N.A.
|
[1] |
9
|
D0FK0Y
|
Drug Info
|
N.A.
|
[1] |
10
|
D0FS3J
|
Drug Info
|
N.A.
|
[1] |
11
|
D0KO2E
|
Drug Info
|
N.A.
|
[1] |
12
|
D0MQ7F
|
Drug Info
|
N.A.
|
[1] |
13
|
D0R6EF
|
Drug Info
|
N.A.
|
[1] |
14
|
D0UL9W
|
Drug Info
|
N.A.
|
[1] |
15
|
D0YO2O
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2008113360 |
Title |
4- [2- (4-Methylphenylsulfanyd-Phenyl] Piperidine with Combined Serotonin and Norepinephrine Reuptake Inhibition for The Treatment of Adhd, Melancholia, Treatment Resistent Depression or Residual Symptoms In Depression. |
Abstract |
The use of 4-[2-(4-methylphenylsulfayl)phenyl]peridine and acid additions salts thereof for the treatment of ADHD, melancholia, treatment resistant depression or residual.symptoms in depression is provided. |
Applicant(s) |
H. Lundbeck A/S |
Representative Drug(s) |
D06YCW |
Drug Info
|
N.A. |
[1] |
Patent ID |
WO2006116165 |
Title |
Chromane and Chromene Derivatives and Uses Thereof. |
Abstract |
Compounds of formula I or pharmaceutically acceptable salts thereof are provided: wherein each of R1, R2, R3, R4, y, m, n, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia. |
Applicant(s) |
HEFFERNAN, Gavin, David et al |
Representative Drug(s) |
D0WR7F |
Drug Info
|
N.A. |
[1] |
Patent ID |
WO2003091250 |
Title |
[1,4]Diazepino[6,7,1-Ij]Quinoline Derivatives As Anti Psychotic and Antiobesity Agents. |
Abstract |
Compounds of formula 1 or a pharmaceutically acceptable salt thereof are provided: I where R1 through R7 are defined herein. The compounds of formula I are 5HT2c agonists or partial agonists, and are useful for treating a variety of disorders. |
Applicant(s) |
RAMAMOORTHY, Sivaramakrishnan, P et al |
Representative Drug(s) |
D01LVT |
Drug Info
|
N.A. |
[1] |
Patent ID |
WO2009063993 |
Title |
Fused Pyridine Derivative and Use Thereof. |
Abstract |
Disclosed is a serotonin 5-HT2c receptor activator containing a compound represented by the formula (I) below or a salt thereof. (In the formula, the symbols are as defined in the description.). |
Applicant(s) |
Takeda Pharmaceutical |
Patent ID |
WO2009063992 |
Title |
Condensed Pyridine Derivative and Use Thereof. |
Abstract |
Provided are a condensed pyridine derivative having an action of activating a serotonin 5HT2c receptor, a preventive or therapeutic agent for a disease such as lower urinary tract symptom, obesity and. |
Applicant(s) |
Takeda Pharmaceutical Company Limited |
Patent ID |
WO2009063991 |
Title |
Pyridooxazepine Derivative and Use Thereof. |
Abstract |
Disclosed is a compound represented by the formula below, which has excellent serotonin 5-HT2C receptor activating activity. Specifically disclosed is a compound represented by the formula below or a salt thereof. (In the formula, A represents -OR1 or -S(O)pR2; R1 and R2 each represent a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group; and p represents 0, 1 or 2.). |
Applicant(s) |
Takeda Pharmaceutical Co., Ltd |
Patent ID |
WO2008117169 |
Title |
Pyrimido [4, 5-D] Azepine Derivatives As 5-Ht2C Agonists. |
Abstract |
The present invention relates to compounds of formula (I): wherein R1, R2, R3a, R3b, R3c, R3d and R100 are as defined in the specification. These compounds act as 5-HT2C agonists. |
Applicant(s) |
Pfizer Limited |
Patent ID |
WO2008108445 |
Title |
Benzoxazepine Derivatives and Use Thereof. |
Abstract |
Compounds represented by the general formula (I) wherein each symbol is as defined in the description [with the proviso that 9-chloro-7-(1,1-dimethylethyl)-2,3,4,5-tetrahydro-1,4-benz-oxazepine and N-. |
Applicant(s) |
Takeda Pharmaceutical Company Limited |
Patent ID |
WO2008052078 |
Title |
Benzoxathiine and Benzoxathiole Derivatives and Uses Thereof. |
Abstract |
Compounds of formula (I) or pharmaceutically acceptable salts thereof are provided, wherein each of R1, R2, R3, R4, y, n, m, p, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia. |
Applicant(s) |
STACK, Gary, Paul et al |
Patent ID |
WO2007028082 |
Title |
6-Substituted- 2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines As 5-Ht2C Receptor Agonists. |
Abstract |
The present invention provides 6-substituted 2,3,4,5-tetrahydro-lH- benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: R6 D R N-R' R* where R6 is -(CrC3)alkyl-S-(C0-C3)alkyl-R10, -(C1-C3)alkyl-NR11R12, -(CrC3)alkyl-O- R 13. and other substituents are as defined in the specification. |
Applicant(s) |
Eli Lilly and Company |
Patent ID |
WO2006116158 |
Title |
Benzodioxane and Benzodioxolane Derivatives and Uses Thereof. |
Abstract |
Compounds of formula (I) or pharmaceutically acceptable salts thereof are provided, wherein each of R1, R2, R3, R4, y, n, m, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia. |
Applicant(s) |
ZHOU, Dahui et al |
Patent ID |
WO2006116150 |
Title |
Dihydrobenzofuran Derivatives and Uses Thereof. |
Abstract |
Compounds of formula (I) are described herein which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. Formula (I), or pharmaceutically acceptable salts thereof, wherein each of R1, R2, R3, R4, Rx, Ry, and n are as defined herein. Such compounds, and compositions thereof, are useful for treating a variety of central nervous system disorders such as schizophrenia. |
Applicant(s) |
STACK, Gary Paul et al |
Patent ID |
WO2006050007 |
Title |
Substituted Indolizines and Derivatives As Cns Agents. |
Abstract |
Compounds of formula (I) of pharmaceutically acceptable salts thereof are provided: formula (I), which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia. |
Applicant(s) |
SABB, Annmarie, Louise et al |
Patent ID |
WO2005082859 |
Title |
6-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines As 5-Ht2C Receptor Agonists. |
Abstract |
The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: I where: R6 is -C=C-R10, -O-R12, -S-R14, or -NR24R25; and other substituents are as defined in the specification. |
Applicant(s) |
Eli Lilly and Company |
Patent ID |
WO2005044812 |
Title |
Dihydrobenzofuranyl Alkanamine Derivatives As 5Ht2C Agonists. |
Abstract |
Compounds of Formula (I) or pharmaceutically acceptable salts thereof are provided: Formula (I) which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia. |
Applicant(s) |
GROSS, Jonathan, Laird et al |
Patent ID |
WO2005040146 |
Title |
Dihydrobenzofuranyl Alkanamines and Pharmaceutical Compositions Containing Them. |
Abstract |
Compounds of formula (1) or pharmaceutically acceptable salts thereof are provided : Formula (1) which are agonists and partial agonists of the 2c subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia. |
Applicant(s) |
GROSS, Jonathan, Laird et al |
Patent ID |
WO2005019180 |
Title |
6-(2,2,2-Trifluoroethylamino)-7-Chloro-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepine As A 5-Ht2C Receptor Agonist. |
Abstract |
The present invention provides a 7-chloro-6-(2,2,2-trifluoroethylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine of formula (I): or a pharmaceutically acceptable salt thereof, and its use as a selective 5-HT2c agonist for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, anxiety, and depression. |
Applicant(s) |
Eli Lilly and Company |
Patent ID |
WO2008052096 |
Title |
Benzodioxane Derivatives and Uses Thereof. |
Applicant(s) |
FITZWATER, Kelly, R et al |
Patent ID |
WO2008007664 |
Title |
Bicyclic Heterocyclic Compound and Use Thereof. |
Applicant(s) |
Takeda Pharmaceutical Company Limited |
Patent ID |
WO2008007661 |
Title |
Tricyclic Heterocyclic Compound and Use Thereof. |
Applicant(s) |
Takeda Pharmaceutical Company Limited |
Patent ID |
WO2007132841 |
Title |
Fused Heterocyclic Compound and Use Thereof. |
Applicant(s) |
Takeda Pharmaceutical Company Limited |
Patent ID |
WO2006103511 |
Title |
5-Ht2C Receptor Modulators. |
Applicant(s) |
Pfizer Products, Inc |
United States Patent and Trademark Office (USPTO) |
Patent ID |
US8618288 |
Title |
Pyrimidine Compounds As Serotonin Receptor Modulators. |
Applicant(s) |
Janssen Pharmaceutica Nv |
Representative Drug(s) |
D00YGY |
Drug Info
|
Ki = 20 nM |
Click to Show More |
[1] |
2
|
D0P9VX
|
Drug Info
|
Ki = 70 nM
|
[1] |
3
|
D0B7NS
|
Drug Info
|
Ki = 90 nM
|
[1] |
4
|
D0N2VA
|
Drug Info
|
Ki = 900 nM
|
[1] |
5
|
D0U9UH
|
Drug Info
|
Ki = 1020 nM
|
[1] |
6
|
D0SE9K
|
Drug Info
|
Ki = 1170 nM
|
[1] |
7
|
D08DJY
|
Drug Info
|
Ki = 1000 nM
|
[1] |
Patent ID |
US7863442 |
Title |
Processes for The Synthesis of Olanzapine. |
Applicant(s) |
Apotex Pharmachem Inc |
Representative Drug(s) |
D01PAP |
Drug Info
|
N.A. |
[1] |
Patent ID |
US7425627 |
Title |
Methods of Synthesizing Olanzapine. |
Applicant(s) |
Teva Pharmaceutical Industries Ltd |
Representative Drug(s) |
D01PAP |
Drug Info
|
N.A. |
[1] |
Patent ID |
US7329747 |
Title |
Synthesis of Olanzapine and Intermediates Thereof. |
Applicant(s) |
Synthon Ip Inc |
Representative Drug(s) |
D01PAP |
Drug Info
|
N.A. |
[1] |
Patent ID |
US7022698 |
Title |
Pharmaceutical Compositions Containing New Polymorphic forms of Olanzapine and Uses Thereo. |
Applicant(s) |
U & I Pharmaceuticals, Ltd |
Representative Drug(s) |
D01PAP |
Drug Info
|
N.A. |
[1] |
Patent ID |
US6740753 |
Title |
Crystal Olanzapine with A Melting Point of 187-191 Degrees C. |
Applicant(s) |
Geneva Pharmaceuticals, Inc |
Representative Drug(s) |
D01PAP |
Drug Info
|
N.A. |
[1] |
Patent ID |
US6506746 |
Title |
Such As AlzheimerS Disease, By Administering Olanzapine or Salt Thereof. |
Applicant(s) |
Eli Lilly and Company |
Representative Drug(s) |
D01PAP |
Drug Info
|
N.A. |
[1] |
Patent ID |
US6147072 |
Title |
Administering Antidepressant and Serotonin Reuptake Inhibitor. |
Applicant(s) |
Eli Lilly and Company |
Representative Drug(s) |
D01PAP |
Drug Info
|
N.A. |
[1] |
Patent ID |
US5627178 |
Title |
Treating Central Nervous System Disorders. |
Applicant(s) |
Lilly Industries Limited |
Representative Drug(s) |
D01PAP |
Drug Info
|
N.A. |
[1] |
Patent ID |
US20110319395 |
Title |
Pharmaceutical formulation of Olanzapine. |
Applicant(s) |
Krka, Tovarna Zdravil, Dd |
Representative Drug(s) |
D01PAP |
Drug Info
|
N.A. |
[1] |
Patent ID |
US20120058185 |
Title |
Stable Pharmaceutical Compositions of Olanzapine and Process for Their Preparation. |
Representative Drug(s) |
D01PAP |
Drug Info
|
N.A. |
[1] |